{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:32:37Z","timestamp":1792096357182,"version":"4.4.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster (shingles) and its complications in older adults. In this prospective, postlicensure Vaccine Safety Datalink study using electronic health records, we sequentially monitored a real-world population of adults aged \u226550 years who received care in multiple US Vaccine Safety Datalink health systems to identify potentially increased risks of 10 prespecified health outcomes, including stroke, anaphylaxis, and Guillain-Barr\u00e9 syndrome (GBS). Among 647,833 RZV doses administered from January 2018 through December 2019, we did not detect a sustained increased risk of any monitored outcome for RZV recipients relative to either historical (2013\u20132017) recipients of zoster vaccine live, a live attenuated virus vaccine (Zostavax; Merck &amp; Co., Inc., Kenilworth, New Jersey), or contemporary non-RZV vaccine recipients who had an annual well-person visit during the 2018\u20132019 study period. We confirmed prelicensure trial findings of increased risks of systemic and local reactions following RZV. Our study provides additional reassurance about the overall safety of RZV. Despite a large sample, uncertainty remains regarding potential associations with GBS due to the limited number of confirmed GBS cases that were observed.<\/jats:p>","DOI":"10.1093\/aje\/kwac170","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T08:30:33Z","timestamp":1664613033000},"page":"205-216","source":"Crossref","is-referenced-by-count":27,"title":["Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data"],"prefix":"10.1093","volume":"192","author":[{"given":"Jennifer C","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ulloa-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onchee","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A","family":"Belongia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Harpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse O","family":"Kharbanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L","family":"Naleway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Fu","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Katherine","family":"Yih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"2023020606385227000_ref1","author":"Food and Drug Administration, US Department of Health and Human Services","year":"2017"},{"issue":"3","key":"2023020606385227000_ref2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2023020606385227000_ref3","author":"Food and Drug Administration, US Department of Health and Human Services","year":"2006"},{"issue":"11","key":"2023020606385227000_ref4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med."},{"issue":"22","key":"2023020606385227000_ref5","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med."},{"issue":"22","key":"2023020606385227000_ref6","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med."},{"issue":"12","key":"2023020606385227000_ref7","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis."},{"issue":"6","key":"2023020606385227000_ref8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis."},{"key":"2023020606385227000_ref9","author":"Lee","year":"2021"},{"issue":"18","key":"2023020606385227000_ref10","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","article-title":"Safety profile of adjuvanted recombinant zoster vaccine: pooled analysis of two large randomized phase 3 trials","volume":"37","author":"L\u00f3pez-Fauqued","year":"2019","journal-title":"Vaccine."},{"issue":"18","key":"2023020606385227000_ref11","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Tavares-Da-Silva","year":"2020","journal-title":"Vaccine."},{"issue":"4","key":"2023020606385227000_ref12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix)\u2014United States, October 2017\u2013June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"36","key":"2023020606385227000_ref13","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine."},{"issue":"12","key":"2023020606385227000_ref14","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barr\u00e9 syndrome following recombinant zoster vaccine in Medicare beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern Med."},{"issue":"suppl 1","key":"2023020606385227000_ref15","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1542\/peds.2010-1722H","article-title":"The Vaccine Safety Datalink: a model for monitoring immunization safety","volume":"127","author":"Baggs","year":"2011","journal-title":"Pediatrics."},{"issue":"2","key":"2023020606385227000_ref16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ije\/dyi274","article-title":"Evidence of bias in estimates of influenza vaccine effectiveness in seniors","volume":"35","author":"Jackson","year":"2006","journal-title":"Int J Epidemiol."},{"issue":"2","key":"2023020606385227000_ref17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/aje\/kws317","article-title":"Adapting group sequential methods to observational post-licensure safety surveillance: results of a pentavalent combination DTaP-IPV-Hib (Pentacel) vaccine safety study","volume":"177","author":"Nelson","year":"2013","journal-title":"Am J Epidemiol."},{"issue":"10 suppl 2","key":"2023020606385227000_ref18","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/MLR.0b013e3180616c0a","article-title":"Real-time vaccine safety surveillance for the early detection of adverse events","volume":"45","author":"Lieu","year":"2007","journal-title":"Med Care"},{"issue":"32","key":"2023020606385227000_ref19","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1016\/j.vaccine.2009.05.036","article-title":"An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink","volume":"27","author":"Yih","year":"2009","journal-title":"Vaccine."},{"issue":"1","key":"2023020606385227000_ref20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics."},{"issue":"1","key":"2023020606385227000_ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/INF.0b013e3181af8605","article-title":"Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine","volume":"29","author":"Belongia","year":"2010","journal-title":"Pediatr Infect Dis J."},{"issue":"46","key":"2023020606385227000_ref22","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine."},{"issue":"2","key":"2023020606385227000_ref23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink Project","volume":"41","author":"Lee","year":"2011","journal-title":"Am J Prev Med."},{"issue":"22","key":"2023020606385227000_ref24","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.vaccine.2013.03.040","article-title":"Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children","volume":"31","author":"Tseng","year":"2013","journal-title":"Vaccine."},{"issue":"25","key":"2023020606385227000_ref25","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.vaccine.2014.03.063","article-title":"Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine","volume":"32","author":"Daley","year":"2014","journal-title":"Vaccine."},{"issue":"8","key":"2023020606385227000_ref26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pds.3996","article-title":"Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013\u20132014 and 2014\u20132015 seasons","volume":"25","author":"Li","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"2023020606385227000_ref27","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1808","article-title":"Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine","volume":"144","author":"Donahue","year":"2019","journal-title":"Pediatrics."},{"issue":"3","key":"2023020606385227000_ref28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.ede.0000155506.05636.a4","article-title":"Active surveillance of vaccine safety: a system to detect early signs of adverse events","volume":"16","author":"Davis","year":"2005","journal-title":"Epidemiology."},{"issue":"6","key":"2023020606385227000_ref29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/pds.2133","article-title":"Near real-time vaccine safety surveillance with partially accrued data","volume":"20","author":"Greene","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"2023020606385227000_ref30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jval.2010.10.033","article-title":"The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health."},{"issue":"3","key":"2023020606385227000_ref31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.0006-341X.1999.00874.x","article-title":"A unifying family of group sequential test designs","volume":"55","author":"Kittleson","year":"1999","journal-title":"Biometrics."},{"issue":"4","key":"2023020606385227000_ref32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/sim.8410","article-title":"Safety surveillance and the estimation of risk in select populations: flexible methods to control for confounding while targeting marginal comparisons","volume":"39","author":"Shi","year":"2020","journal-title":"Stat Med."},{"key":"2023020606385227000_ref33","volume-title":"Generalized Additive Models","author":"Hastie","year":"1990"},{"key":"2023020606385227000_ref34","volume-title":"SHINGRIX* (Zoster Vaccine Recombinant, Adjuvanted)","author":"Vaccines and Related Biological Products Advisory Committee, Food and Drug Administration, US Department of Health and Human Services","year":"2017"},{"issue":"12","key":"2023020606385227000_ref35","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216639","article-title":"Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares","volume":"80","author":"Didierlaurent","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"14","key":"2023020606385227000_ref36","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA."},{"issue":"1","key":"2023020606385227000_ref37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/pds.3310","article-title":"Validation of acute myocardial infarction in the Food and Drug Administration\u2019s Mini-Sentinel Program","volume":"22","author":"Cutrona","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"suppl 10","key":"2023020606385227000_ref38","doi-asserted-by":"crossref","first-page":"K7","DOI":"10.1016\/j.vaccine.2013.04.040","article-title":"A systematic review of validated methods for identifying Bell\u2019s palsy using administrative or claims data","volume":"31","author":"Lee","year":"2013","journal-title":"Vaccine."},{"issue":"3","key":"2023020606385227000_ref39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/EDE.0000000000001330","article-title":"Identification and validation of anaphylaxis using electronic health data in a population-based setting","volume":"32","author":"Bann","year":"2021","journal-title":"Epidemiology."},{"issue":"11","key":"2023020606385227000_ref40","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/pds.3505","article-title":"Validation of anaphylaxis in the Food and Drug Administration\u2019s Mini-Sentinel","volume":"22","author":"Walsh","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"3","key":"2023020606385227000_ref41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/oxfordjournals.aje.a009804","article-title":"Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies","volume":"149","author":"Guevara","year":"1999","journal-title":"Am J Epidemiol."},{"issue":"9","key":"2023020606385227000_ref42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamapediatrics.2013.186","article-title":"Identifying pediatric community-acquired pneumonia hospitalizations: accuracy of administrative billing codes","volume":"167","author":"Williams","year":"2013","journal-title":"JAMA Pediatr."},{"issue":"11","key":"2023020606385227000_ref43","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis."},{"issue":"2","key":"2023020606385227000_ref44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/rssb.12361","article-title":"Multiply robust causal inference with double negative control adjustment for categorical unmeasured confounding","volume":"82","author":"Shi","year":"2020","journal-title":"J R Stat Soc Ser B Stat Methodol."}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwac170\/46874894\/kwac170.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/192\/2\/205\/49088253\/kwac170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/192\/2\/205\/49088253\/kwac170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T01:40:08Z","timestamp":1675647608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/192\/2\/205\/6747774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,4]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwac170","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2022,10,4]]}}}